Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS TumorsCIRB: Pediatric CIRBLead Group: COGStatus: ActiveReview Status: Available to Open